We previously demonstrated that cardiac hypertrophy and fibrosis in GC-A KO mice can be significantly diminished by targeted deletion of AT1a (double KO for GC-A and AT1a) or by pharmacological blockade of the receptor using a selective antagonist [27]. The gene discussed is GCA; the disease is cardiac hypertrophy.